PHILADELPHIA, PA, UNITED STATES - Jun 24, 2019 - ERT, a global data and technology company that minimizes uncertainty and risk in clinical trials, today announced its involvement in a groundbreaking project to enhance drug development and improve the clinical management of mobility loss. The clinical research project ─ MOBILISE-D ─ will establish a roadmap to implement new digital tools for analysis of motion to identify, categorize, and monitor patient disability.

Professor Lynn Rochester, Professor of Human Movement Science at Newcastle University is coordinating the MOBILISE-D consortium, which is comprised of clinicians and scientists from academic centers across Europe. “Digital technologies, including sensors worn on the body, have the potential to transform how we assess mobility and identify life-changing conditions,” stated Professor Rochester. “They have the potential to enable medical teams to intervene earlier and offer treatment to extend healthy life, which is especially important considering the ageing population and the growing number of people living with chronic health conditions today.”

“We’re honored to participate in this important project as part of our commitment to improving clinical research and aiding the industry in delivering more effective, personalized healthcare,” said David Elario, Executive Vice President, eCOA, ERT.

ERT scientists are contributing their expertise on scale validation, real-time movement characterization and combined objective / subjective monitoring systems to the project, which is   targeting the development of device-provided outcome measures for Parkinson’s disease, multiple sclerosis, hip fracture recovery, (Proximal Femoral Fracture, PFF), and congestive heart failure.

“New interventions are a key focus, but to accelerate their development, better methods are needed to predict, detect and measure mobility loss and restoration,” said Stephen Raymond, PhD, Chief Scientist, Scientific Affairs at ERT. “We see tremendous value in characterizing the context of motion episodes as well as the significance of mobility limitations to the individual.”

ERT scientists will present some of their recent findings on improving patient reported outcomes through the capture of eCOA data at the Drug Information Association (DIA) Annual Meeting, June 23-27. Visit Dr. Raymond at booth #1231.

Find more of ERT’s research on improving patient reported outcomes through electronic Clinical Outcomes Assessment (eCOA) at ert.com/eCOA.

###

About ERT
ERT is a global data and technology company that minimizes uncertainty and risk in clinical trials so that its customers can move ahead with confidence. With nearly 50 years of clinical and therapeutic experience, ERT balances knowledge of what works with a vision for what’s next, so it can adapt without compromising standards.

Powered by the company’s EXPERT® technology platform, ERT’s solutions enhance trial oversight, enable site optimization, increase patient engagement and measure the efficacy of new clinical treatments while ensuring patient safety. Since 2013, more than half of all FDA drug approvals came from ERT-supported studies. Pharma companies, biotechs and CROs have relied on ERT solutions across 15,000 studies, spanning more than four million patients to date. By identifying trial risks before they become problems, ERT enables customers to bring clinical treatments to patients quickly ─ and with confidence.

For more information, go to ert.com or follow us on LinkedIn and Twitter.